Implanet Announces Its 2020 Financial Calendar

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0010458729, eligibile for PEA-PME equity savings plans; OTCQX: IMPZY) (Paris:ALIMP) (OTCQX:IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announces its schedule for the publication of financial information for 2020.

Event

Dates*

2019 Full-Year Annual Revenue

January 21, 2020

2019 Full-Year Results

February 24, 2020

Annual General Meeting

April 7, 2020

2020 First-Quarter Revenue

April 21, 2020

2020 First-Half Revenue

July 7, 2020

2020 First-Half Results

September 15, 2020

2020 Third-Quarter Revenue

October 13, 2020

(*): These dates can be subject to modifications. Press releases will be published after market close.

Next financial press release: 2019 annual revenue, on Tuesday January 21st, 2020 (after market)

About Implanet

Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity is based on 2 main product ranges, the JAZZ® latest-generation implant, aimed at treating spinal pathologies requiring vertebral fusion surgery and MADISON, its implant for first-line knee protrhetic surgery. Implanet’s tried-and-tested orthopedic platform, which is based on perfect control over the traceability of its products, provides it with a proven ability to promote these innovations. Protected by four families of international patents, JAZZ® and MADISON have obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE marking. Implanet employs 38 staff and recorded 2018 revenue of €6.7 million. For further information, please visit www.Implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Contacts

IMPLANET
Ludovic Lastennet, CEO

David Dieumegard, CFO

Tel.: +33(0)5 57 99 55 55

investors@Implanet.com

NewCap
Investor Relations

Sandrine Boussard-Gallien

Tel.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

NewCap
Media Relations

Nicolas Merigeau

Tel.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

Staff

Recent Posts

MyndTec Inc. Completes Fourth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - March 19, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the…

5 hours ago

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on…

7 hours ago

Vytalize Health Named to Forbes’ 2024 List of America’s Best Startup Employers

Prestigious business publication recognizes the value-based care enabler for its employer reputation, employee satisfaction, and…

7 hours ago

Masimo Named One of Fast Company’s Most Innovative Companies in North America

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

10 hours ago

The Assistance Fund Becomes a Member of the National Health Council

ORLANDO, FL / ACCESSWIRE / March 19, 2024 / The Assistance Fund (TAF), an independent…

10 hours ago

Cell MedX Corp. Closes Private Placement Financing

Vancouver, British Columbia--(Newsfile Corp. - March 19, 2024) - Cell MedX Corp. (OTC Pink: CMXC)…

11 hours ago